According to EULAR (the European League Against Rheumatism), OARSI (Osteoarthritis Research Society International) and WHO (World Health Organization), the musculoskeletal or rheumatic diseases are the major cause of morbidity throughout the world, having a substantial influence on health and quality of life, also causing an enormous burden of cost on health systems. Osteoarthritis is an important example of more than 150 conditions and syndromes with the common denominators of pain and inflammation. The 40% of people over the age of 70 years suffer from osteoarthritis of the knee, 80% of patients with osteoarthritis have some degrees of limitation of movement, and 25% cannot perform their major activities of daily living.
Analgesic and anti-inflammatory drugs alleviate pain quickly but are not able to change the disease's development, as the symptoms reappear once the treatment stops.
Chondroprotectors like chondroitin sulfate have a slow symptomatic action and have a demonstrated symptomatic efficacy.
Mythocondro® is the first and only Non-Animal Chondroitin Sulfate produced by a patented fermentation-based manufacturing process. The result of this innovative approach is a Non-Animal CS with homogeneous structure and a constant charge density and molecular mass parameters, like in human synovial fluid and compliant to USP monograph of Chondroitin Sulfate Sodium.
Animal Chondroitin Sulfate can be obtained through a process of extraction and purification from animal cartilage, variety of extraction and purification techniques can be applied resulting in different Chondroitin Sulfate contents, structure, properties and activities.
Today, along with traditional use of drugs to treat the pain of OA, great results are associated with administering chondroprotective bioactive (macro)molecules in the early stages of OA, in order to delay progress and/or to reduce symptoms.
Chondroitin Sulfate (CS), a basic natural components of cartilage and synovial fluid, is one of the most effective Symptomatic Slow-Acting Drugs for Osteoarthritis (SYSADOAs) and is a S/DMOAD (Structure/Disease Modifying Anti-Osteoarthritis Drug) used to provide relief from the pain and inflammation associated with joint degeneration. Its supplementation helps to regenerate the joint structure, leading to reduced pain and increased mobility of the affected joint. The clinical benefits of CS have been established by a large number of human trials and offers an excellent safety and tolerability profile which allows long term administration for OA and joint health.
Mythocondro® is a revolutionary ingredient, patented and developed by Gnosis using a pharmaceutical approach, to ensure strict quality standards that promises to change completely the CS industry, providing a reliable and reproducible source of CS which definitely solves concerns related to animal derived CS: clinically tested, well characterized and environmentally friendly, it is the first Chondroitin Sulfate suitable for vegetarians and free from restrictions of use related to religious and supply issues.